Adverse events in diabetes drug trial.
Christoph
C
Pechlaner
D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D000069450:Liraglutide; D010455:Peptides / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012449:Safety; D016896:Treatment Outcome; D014688:Venoms / Q000009:adverse effects*
D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide